Biglia Nicoletta, Zanfagnin Valentina, Daniele Alberto, Robba Elisabetta, Bounous Valentina E
Obstetrics and Gynaecology Unit, Umberto I Hospital, Department of Surgical Sciences, School of Medicine, University of Turin, Turin, Italy
Obstetrics and Gynaecology Unit, Umberto I Hospital, Department of Surgical Sciences, School of Medicine, University of Turin, Turin, Italy.
Anticancer Res. 2017 Aug;37(8):4005-4015. doi: 10.21873/anticanres.11785.
Lower body lymphedema is a chronic condition and a significant cause of morbidity following treatment of gynecologic cancer that strongly impacts patients' quality of life (QoL). Most studies on secondary lymphedema have been performed on the upper limb after breast cancer treatment and much less is known about lower body lymphedema after gynecologic malignancies. This review focuses on secondary lymphedema due to gynecologic cancer treatment, analyzing its incidence in the different types of gynecologic cancer, diagnosis, risk factors, impact on QoL and treatment. A systematic search of Medline has been performed to track the studies evaluating lower body lymphedema after treatment for endometrial, ovarian, cervical and vulvar cancer. Unfortunately, there is no consensus about a uniform evaluation and, as a consequence, the reported incidence is broadly different among the studies. Standardization in lymphedema evaluation is required to better compare the outcome of different types of treatment.
下肢淋巴水肿是一种慢性疾病,是妇科癌症治疗后发病的一个重要原因,对患者的生活质量(QoL)有很大影响。大多数关于继发性淋巴水肿的研究是在乳腺癌治疗后的上肢进行的,而对于妇科恶性肿瘤后下肢淋巴水肿的了解则少得多。本综述聚焦于妇科癌症治疗所致的继发性淋巴水肿,分析其在不同类型妇科癌症中的发病率、诊断、危险因素、对生活质量的影响及治疗。我们对医学文献数据库(Medline)进行了系统检索,以追踪评估子宫内膜癌、卵巢癌、宫颈癌和外阴癌治疗后下肢淋巴水肿的研究。遗憾的是,目前尚无关于统一评估的共识,因此各研究报告的发病率差异很大。需要对淋巴水肿评估进行标准化,以便更好地比较不同类型治疗的结果。